Universal protein vaccines against Neisseria meningitidis serogroup B, Streptococcus pneumoniae and influenza

Nicola Principi, Susanna Esposito

Research output: Contribution to journalArticle

Abstract

Traditional vaccines can only be really effective when the antigenic diversity or variability of the micro-organisms in the same bacterial species or viral family is no more than marginally different, and when protection is mainly dependent from antibody-mediated immunity. One solution is to identify the antigens common to all of the strains in a species or family that are significantly capable of eliciting inactivating antibodies. A number of attempts have recently been made to develop vaccines with conserved and highly immunogenic antigens made using various and sometimes highly innovative approaches. Although none of these vaccines has yet been licensed for human use, some have been widely studied in experimental animals and humans, and seem to increase the possibility of preventing previously uncovered or only partially covered infectious diseases. This review provides a detailed description of the most important new information concerning protein vaccines against influenza and meningococcal and pneumococcal diseases.

Original languageEnglish
Pages (from-to)905-912
Number of pages8
JournalHuman Vaccines
Volume7
Issue number9
DOIs
Publication statusPublished - Sep 2011

Fingerprint

Serogroup B Neisseria meningitidis
Streptococcus pneumoniae
Human Influenza
Antigenic Variation
Vaccines
Meningococcal Vaccines
Antigens
Proteins
Antibodies
Influenza Vaccines
Communicable Diseases
Immunity

Keywords

  • Influenza
  • Neisseria meningitidis
  • Protein vaccines
  • Streptococcus pneumoniae
  • Vaccines

ASJC Scopus subject areas

  • Immunology
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Universal protein vaccines against Neisseria meningitidis serogroup B, Streptococcus pneumoniae and influenza. / Principi, Nicola; Esposito, Susanna.

In: Human Vaccines, Vol. 7, No. 9, 09.2011, p. 905-912.

Research output: Contribution to journalArticle

Principi, Nicola ; Esposito, Susanna. / Universal protein vaccines against Neisseria meningitidis serogroup B, Streptococcus pneumoniae and influenza. In: Human Vaccines. 2011 ; Vol. 7, No. 9. pp. 905-912.
@article{fcb6daa0851f4d4fae099ab0f6535822,
title = "Universal protein vaccines against Neisseria meningitidis serogroup B, Streptococcus pneumoniae and influenza",
abstract = "Traditional vaccines can only be really effective when the antigenic diversity or variability of the micro-organisms in the same bacterial species or viral family is no more than marginally different, and when protection is mainly dependent from antibody-mediated immunity. One solution is to identify the antigens common to all of the strains in a species or family that are significantly capable of eliciting inactivating antibodies. A number of attempts have recently been made to develop vaccines with conserved and highly immunogenic antigens made using various and sometimes highly innovative approaches. Although none of these vaccines has yet been licensed for human use, some have been widely studied in experimental animals and humans, and seem to increase the possibility of preventing previously uncovered or only partially covered infectious diseases. This review provides a detailed description of the most important new information concerning protein vaccines against influenza and meningococcal and pneumococcal diseases.",
keywords = "Influenza, Neisseria meningitidis, Protein vaccines, Streptococcus pneumoniae, Vaccines",
author = "Nicola Principi and Susanna Esposito",
year = "2011",
month = "9",
doi = "10.4161/hv.7.9.15986",
language = "English",
volume = "7",
pages = "905--912",
journal = "Human Vaccines",
issn = "1554-8600",
publisher = "Landes Bioscience",
number = "9",

}

TY - JOUR

T1 - Universal protein vaccines against Neisseria meningitidis serogroup B, Streptococcus pneumoniae and influenza

AU - Principi, Nicola

AU - Esposito, Susanna

PY - 2011/9

Y1 - 2011/9

N2 - Traditional vaccines can only be really effective when the antigenic diversity or variability of the micro-organisms in the same bacterial species or viral family is no more than marginally different, and when protection is mainly dependent from antibody-mediated immunity. One solution is to identify the antigens common to all of the strains in a species or family that are significantly capable of eliciting inactivating antibodies. A number of attempts have recently been made to develop vaccines with conserved and highly immunogenic antigens made using various and sometimes highly innovative approaches. Although none of these vaccines has yet been licensed for human use, some have been widely studied in experimental animals and humans, and seem to increase the possibility of preventing previously uncovered or only partially covered infectious diseases. This review provides a detailed description of the most important new information concerning protein vaccines against influenza and meningococcal and pneumococcal diseases.

AB - Traditional vaccines can only be really effective when the antigenic diversity or variability of the micro-organisms in the same bacterial species or viral family is no more than marginally different, and when protection is mainly dependent from antibody-mediated immunity. One solution is to identify the antigens common to all of the strains in a species or family that are significantly capable of eliciting inactivating antibodies. A number of attempts have recently been made to develop vaccines with conserved and highly immunogenic antigens made using various and sometimes highly innovative approaches. Although none of these vaccines has yet been licensed for human use, some have been widely studied in experimental animals and humans, and seem to increase the possibility of preventing previously uncovered or only partially covered infectious diseases. This review provides a detailed description of the most important new information concerning protein vaccines against influenza and meningococcal and pneumococcal diseases.

KW - Influenza

KW - Neisseria meningitidis

KW - Protein vaccines

KW - Streptococcus pneumoniae

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=80053490173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053490173&partnerID=8YFLogxK

U2 - 10.4161/hv.7.9.15986

DO - 10.4161/hv.7.9.15986

M3 - Article

C2 - 21865879

AN - SCOPUS:80053490173

VL - 7

SP - 905

EP - 912

JO - Human Vaccines

JF - Human Vaccines

SN - 1554-8600

IS - 9

ER -